Results of a 275-patient, multi-national phase III clinical trial known as ALTA-1L published today in the New England Journal of Medicine and presented concurrently in the press program at the International Association for the Study of Lung Cancer (IASLC) World Conference on Lung Cancer 2018 argue for brigatinib as a first-line treatment option for advanced...
Tag: <span>Lung cancer</span>
Post
Dental research shows that smoking weakens immune systems
As if lung cancer, emphysema and heart disease weren’t enough, there’s more bad news for cigarette smokers. Researchers at the Case Western Reserve University School of Dental Medicine found that smoking also weakens the ability for pulp in teeth to fight illness and disease. In other words, smokers have fewer defense mechanisms on the inside...
Post
New finding could ‘pause and rewind’ lung cancer
A team of Institute researchers has discovered how to stop and reverse the growth of lung cancer with a potent combination of three molecules. Lung CA seen on CXR. Credit: James Heilman, MD/Wikipedia The study found that two BH3-mimetics and one FGFR inhibitor were able to block lung cancer cell survival so successfully in pre-clinical models that tumors not...
Post
New biomarker identified for early diagnosis of lung cancer
CKAP4 is a potential new diagnostic marker that is detectable in patients with stage I disease and could change current practice in diagnosing lung cancer, reports The American Journal of Pathology Philadelphia, May 8, 2018 – High levels of cytoskeleton-associated protein 4 (CKAP4) have been identified in the blood of patients with lung cancer. In...
Post
Inhibiting metabolism found to be effective in treating aggressive form of lung cancer
Researchers from UCLA and Long Beach Memorial Medical Center have found that two targeted therapies could be more effective if used in combination to treat squamous cell carcinomas of the lung. The two drugs, MLN128 and CB-839, individually target the metabolism of key nutrients glucose and glutamine, respectively, prohibiting cancer from switching metabolic gears between...
Post
Promising drug may stop cancer-causing gene in its tracks
Credit: Michigan State University Michigan State University scientists are testing a promising drug that may stop a gene associated with obesity from triggering breast and lung cancer, as well as prevent these cancers from growing. These findings are based on two studies featured in the latest issue of Cancer Prevention Research. The first was a...
Post
RNA-based therapeutic inhibits a metabolic pathway in tumor-initiating lung cancer cells
RNA-based therapeutics that prevent a key metabolic enzyme from being expressed in tumor-initiating cells (TIC) hold promise for the treatment of lung cancer, an A*STAR team has shown. As implied by their name, TIC – also known as cancer stem cells – are a subset of tumor cells with the capacity to self-renew and start new tumors. Abnormal metabolism is...
Post
Encouraging oxygen’s assault on iron may offer new way to kill lung cancer cells
Blocking the action of a key protein frees oxygen to damage iron-dependent proteins in lung and breast cancer cells, slowing their growth and making them easier to kill. This is the implication of a study led by researchers from Perlmutter Cancer Center at NYU Langone Health, and published online November 22 in Nature. Human cells contain...
Post
Lung cancer triggers pulmonary hypertension
Hypertension associated with lung cancer: In the diagram, a tumour is shown in the right lung. Histological comparison of two blood vessels shows dramatic thickening of the wall of the vessel removed from the tumour region. Changes in blood …more Shortness of breath and respiratory distress often increase the suffering of advanced-stage lung cancer patients....
Post
Tarloxitinib puts tumor-seeking tail on anti-EGFR drug to precisely target lung cancer
EGFR is a common genetic target in lung cancer, but not all EGFR mutations are created equal. Patients with a type of EGFR anomaly called an “EGFR exon 20 insertion” often fail to respond to existing drugs targeting EGFR. Previous work shows this is because it simply takes a much higher concentration of anti-EGFR drugs...